## Arturo Santos

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9402990/publications.pdf

Version: 2024-02-01

430442 500791 2,451 33 18 28 h-index citations g-index papers 33 33 33 2022 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Topical Pirfenidone-Loaded Liposomes Ophthalmic Formulation Reduces Haze Development after Corneal Alkali Burn in Mice. Pharmaceutics, 2022, 14, 316.	2.0	8
2	Liver Cancer: Therapeutic Challenges and the Importance of Experimental Models. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-10.	0.8	18
3	Safety and Tolerability of Topical Ophthalmic Triamcinolone Acetonide-Loaded Liposomes Formulation and Evaluation of Its Biologic Activity in Patients with Diabetic Macular Edema. Pharmaceutics, 2021, 13, 322.	2.0	12
4	Lipid-Based Nanocarriers as Topical Drug Delivery Systems for Intraocular Diseases. Pharmaceutics, 2021, 13, 678.	2.0	23
5	Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration. Pharmaceutics, 2021, 13, 1491.	2.0	4
6	Therapies Based on Nanoparticles for Eye Drug Delivery. Ophthalmology and Therapy, 2020, 9, 1-14.	1.0	31
7	Topical Triamcinolone Acetonide-Loaded Liposomes as Primary Therapy for Macular Edema Secondary to Branch Retinal Vein Occlusion: A Pilot Study. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 393-403.	0.6	11
8	Novel Triamcinolone Acetonide-Loaded Liposomal Topical Formulation Improves Contrast Sensitivity Outcome After Femtosecond Laser-Assisted Cataract Surgery. Journal of Ocular Pharmacology and Therapeutics, 2019, 35, 512-521.	0.6	12
9	Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of DLBCL. Journal of Translational Medicine, 2019, 17, 198.	1.8	8
10	Novel Triamcinolone Acetonide-Loaded Liposomes Topical Formulation for the Treatment of Cystoid Macular Edema After Cataract Surgery: A Pilot Study. Journal of Ocular Pharmacology and Therapeutics, 2019, 35, 106-115.	0.6	20
11	Response to comment on: Feasibility and safety of vitrectomy under topical anesthesia in an office-based setting. Indian Journal of Ophthalmology, 2019, 67, 182.	0.5	0
12	Characterization and Pharmacokinetics of Triamcinolone Acetonide-Loaded Liposomes Topical Formulations for Vitreoretinal Drug Delivery. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 416-425.	0.6	44
13	Surgical Results in Ocriplasmin Candidates With Symptomatic Vitreomacular Traction Syndrome. Current Eye Research, 2018, 43, 208-212.	0.7	O
14	Feasibility and safety of vitrectomy under topical anesthesia in an office-based setting. Indian Journal of Ophthalmology, 2018, 66, 1136.	0.5	11
15	Evaluación de la expresión de marcadores asociados a linfocitos T cooperadores del tipo Th1, Th2, Th17 y Treg en biopsias de pterigión primario. Revista Mexicana De OftalmologÃa, 2018, 92, 26-31.	0.1	O
16	Association of single-nucleotide polymorphisms in non-coding regions of the <i>TLR4</i> gene with primary open angle glaucoma in a Mexican population. Ophthalmic Genetics, 2017, 38, 325-329.	0.5	19
17	Five-Year Safety and Performance Results from the Argus II Retinal Prosthesis System Clinical Trial. Ophthalmology, 2016, 123, 2248-2254.	2.5	281
18	Long-Term Results from an Epiretinal Prosthesis to Restore Sight to the Blind. Ophthalmology, 2015, 122, 1547-1554.	2.5	224

#	Article	IF	CITATIONS
19	Implantable MicroPump for Drug Delivery in Patients with Diabetic Macular Edema. Translational Vision Science and Technology, 2014, 3, 5.	1.1	57
20	One-Year Feasibility Study of Replenish MicroPump for Intravitreal Drug Delivery: A Pilot Study. Translational Vision Science and Technology, 2014, 3, 8.	1.1	20
21	THREE-YEAR SAFETY AND VISUAL ACUITY RESULTS OF EPIMACULAR 90STRONTIUM/90YTTRIUM BRACHYTHERAPY WITH BEVACIZUMAB FOR THE TREATMENT OF SUBFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina, 2012, 32, 10-18.	1.0	28
22	Interim Results from the International Trial of Second Sight's Visual Prosthesis. Ophthalmology, 2012, 119, 779-788.	2.5	675
23	Preliminary 6 month results from the argus <sup>tm</sup> ii epiretinal prosthesis feasibility study., 2009, 2009, 4566-8.		67
24	Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. British Journal of Ophthalmology, 2009, 93, 305-309.	2.1	70
25	TWELVE-MONTH SAFETY AND VISUAL ACUITY RESULTS FROM A FEASIBILITY STUDY OF INTRAOCULAR, EPIRETINAL RADIATION THERAPY FOR THE TREATMENT OF SUBFOVEAL CNV SECONDARY TO AMD. Retina, 2009, 29, 157-169.	1.0	56
26	The role of FABP2 gene polymorphism in alcoholic cirrhosis. Hepatology Research, 2005, 33, 306-312.	1.8	16
27	The e4 allele of apolipoprotein E gene is a potential risk factor for the severity of macular edema in type 2 diabetic Mexican patients. Ophthalmic Genetics, 2002, 23, 13-19.	0.5	30
28	Preservation of the Inner Retina in Retinitis Pigmentosa. JAMA Ophthalmology, 1997, 115, 511.	2.6	606
29	MANAGEMENT OF ENDOPHTHALMITIS IN A SILICONE OIL-FILLED EYE. Retina, 1997, 17, 507-509.	1.0	23
30	Experimental intravitreous cysticercosis. Graefe's Archive for Clinical and Experimental Ophthalmology, 1996, 234, 515-520.	1.0	8
31	Lesions of the Lacrimal Caruncle. Ophthalmology, 1994, 101, 943-949.	2.5	43
32	CONGENITAL HYPERTROPHY OF THE RETINAL PIGMENT EPITHELIUM ASSOCIATED WITH FAMILIAL ADENOMATOUS POLYPOSIS. Retina, 1994, 14, 6-9.	1.0	20
33	Breaking down the Barrier: Topical Liposomes as Nanocarriers for Drug Delivery into the Posterior Segment of the Eyeball. , 0, , .		6